An anti-probasin monoclonal antibody recognizes a novel 40-kDa protein localized in rat liver and a specific region of kidney urinary tubule.

Immunoblotting with a monoclonal antibody against probasin (rat prostatic secretory protein) showed that a 40-kDa protein antigenically related to probasin was localized in rat liver and kidney. The contents of probasin in these organs were negligible. Immunostaining revealed that the 40-kDa protein (probasin-related antigen: PRB-RA) was expressed in the liver parenchymal cells and the kidney urinary tubular epithelial cells in outer stripe. The content of PRB-RA in the kidney was low during 0 to 2 weeks of age, then rapidly increased about 10-fold from 2 to 8 weeks of age. The content in the liver increased about 2-fold during the period, reaching a value of 10-12 ng/micrograms protein, which was ten times higher than that in the kidney. PRB-RA was purified from rat liver by ion-exchange chromatography, gel filtration and fast protein liquid chromatography on a hydroxyapatite column. The purified protein formed insoluble aggregates in the absence of a detergent, and it had a blocked amino terminal. The amino acid sequence of a peptide generated by tryptic digestion of alkylated PRB-RA was determined. Computer analysis showed that there was no protein having a significant homology with the peptide. These results indicate that a novel 40-kDa protein with a structural similarity to probasin is localized in rat liver and kidney, and might bear a function specific to these organs.

The heterogeneity of rat androgen-binding protein in serum differs from that in testis and epididymis.

Fractionation of testicular, epididymal, and serum extracts containing rat androgen-binding protein (rABP) on a Concanavalin A-Sepharose (Con A) column resolved two peaks of immunoreactive protein. The first peak was present in the void volume, and the other was bound by the column and specifically eluted by alpha-methyl-D-glucoside. These two peaks of immunoreactive rABP have been designated form I and form II for the portions of rABP that do not and do bind, respectively, to Concanavalin A. In the course of studying this heterogeneity, we observed that the distribution of the two forms of rABP was the same in the blood and cytosols prepared from testis and epididymis of young rats before the formation of the blood-testis barrier; that is, the ratio of form I to form II ranged from 1:1 to 1:2. Similar heterogeneity was observed in extracts of the reproductive tract from mature animals. However, the blood of adult rats contained reduced amounts of form I relative to form II, so that their ratio was about 1:5. Subsequent studies of infertile rats heterozygous for the Hre gene (Hre/ +), in which total rABP secretion was decreased, and of their normal littermates, indicated that the reduced amount of form I ABP in the sera of mature rats is typical of adult animals regardless of strain or genetic abnormality. The reduced amount of form I relative to form II observed in the blood of adult rats could result from either reduced secretion or increased metabolic clearance of form I in the blood compartment. To distinguish between these possibilities, the blood clearance of the two forms was estimated after orchiectomy. The disappearance rate of form I was not significantly different from that of either form II or unfractionated serum. These results are consistent with reduced release into blood of form I relative to form II rABP rather than increased clearance of form I in adult animals.

Monoclonal antibodies to rat androgen-binding protein recognize both of its subunits and cross-react with rabbit and human testosterone-binding globulin.

A series of four monoclonal antibodies to rat androgen-binding protein (ABP) has been developed. These antibodies recognize both the heavy (48,400-dalton) and light (43,000-dalton) subunits of the native ABP molecule. In addition, they recognize the subunits from which Asn-linked oligosaccharides have been removed by treatment with N-glycanase, indicating that these moieties do not form the immunological determinants recognized by the antibodies. Two of these antibodies are capable of recognizing both nondenatured ABP, as assessed by dot blot analysis, and denatured ABP, as determined by Western blot analysis of ABP after electrophoresis under denaturing conditions. The immunoreactivity of denatured ABP is decreased with two of the antibodies, suggesting that they more readily recognize the antigenic epitopes when the protein is in its native configuration. The antibodies were capable of immunoprecipitating covalently labeled ABP from solution. All four monoclonal antibodies produced were determined to be immunoglobulins M by both enzyme-linked immunosorbent assay and Ouchterlony immunodiffusion even though the initial serum response of the immunized animals indicated the presence of immunoglobulins G. All of the monoclonal antibodies raised against rat ABP cross-reacted with rabbit and human testosterone-binding globulin (TeBG). They were able to detect two subunits when Western blots of intact rabbit [mol wt (Mr, 43,000 and 40,500] or human (Mr, 47,600 and 44,500) TeBG were probed, but only a single subunit (Mr, 39,300) when deglycosylated samples of rabbit TeBG were analyzed.

Androgens transcriptionally regulate the expression of cystatin-related protein and the C3 component of prostatic binding protein in rat ventral prostate and lacrimal gland.

In this report, it is demonstrated that the C3 component of prostatic binding protein (PBP) is also expressed and androgen regulated in the exorbital lacrimal gland, as shown previously for cystatin-related protein (CRP), another abundant secretory protein from the ventral prostate. The presence of C3 messenger RNA (mRNA) could be demonstrated by both Northern blot hybridization and PCR amplification and sequencing. The mRNAs encoding the C1 and C2 components of PBP, however, were undetectable. At the protein level, the C3 component in the lacrimal gland is glycosylated and linked by disulfide bridges to a new 10-kDa component not reacting with the PBP antiserum. As shown previously for CRP, the expression of C3 in the lacrimal gland requires the simultaneous presence of androgens and a functional androgen receptor. The effects of castration and androgen treatment on CRP and C3 mRNA concentrations were studied by Northern blot and dot blot hybridization; effects on transcription rates were determined by nuclear run-on assay. Two days after castration, the relative abundance of CRP mRNA had declined significantly (P < 0.01) to 10.5 +/- 1.5% (+/-SEM) of precastration levels in the prostate and to 14.5 +/- 8.0% in the lacrimal gland; the transcription rates declined to 14.3% and 10.0%, respectively. The C3 mRNA level and transcription rate in the prostate showed a more moderate decrease (P < 0.05) to 40.6 +/- 8.5% and 41.7%, but were hardly measurable in the lacrimal gland. Androgen administration resulted in a rapid increase in the transcription rates, which reached or exceeded control levels after 6-9 h of treatment and clearly preceded the increase in mRNA levels. It is concluded that the lacrimal gland, which can be studied conveniently in female and long term androgen-depleted animals offers a suitable model for the study of androgen-regulated gene expression.

Purification of androgen-binding protein from rat testis using high-performance liquid chromatography and physicochemical properties of the iodinated molecule.

The androgen-binding protein (ABP) has been purified 87,500-fold from rat testis using 4 steps of HPLC, with a yield of 14%. The molecule was 99% pure with a specific activity estimated to 16,600 pmol/mg protein. The iodinated molecule was eluted in 2 peaks in Sephacryl S300 gel filtration with a molecular mass estimated to be 92,600 +/- 3300 and 50,300 +/- 4000 Da. The column isoelectrofocusing of 125I-ABP demonstrated 3 isoproteins isoelectric at pH 4.7, 4.9 and 5.3 and the sedimentation coefficient was estimated to be 4.7 S in sucrose gradient ultracentrifugation. The 125I-ABP had similar physiochemical properties to the non-labelled ABP of epididymis.

Identification of rat prostatic steroid binding protein (PSBP) as an immunosuppressive factor.

Prostatic steroid binding protein (PSBP) is the major protein produced ( approximately 20% of the total cytosolic protein) and secreted into the seminal fluid by the rat ventral prostate but its physiological function has not been elucidated yet. Since PSBP is secreted into the seminal fluid (which is itself a potent immunosuppressor) and has strong homology with uteroglobin (which possess an important anti-inflammatory function) our aim was to determine what effect, if any, PSBP would have on the immune system. With that purpose in mind we performed mononuclear cell cultures in the presence or absence of purified PSBP and analysed the effect of this protein on different functional parameters. PSBP inhibits the mitogen-induced proliferation of normal rat spleen mononuclear cells (MNC) specifically and in a dose-dependent manner. It reduces the production of IL-2 and the expression of its receptor (analysed by flow cytometry) which are important events for lymphocyte proliferation. Also, PSBP was able to inhibit OVA-specific proliferation of lymph node cells from previously primed animals. The immunosuppressive effect of PSBP is not due to an inherent toxic effect to the cells, since the cell viability was kept intact at the different times of culture studied. We also analysed the effect of rat PSBP on mitogen-induced proliferation of mouse spleen and human blood MNC. The proliferation was strongly abolished in a dose-dependent and non-species specific fashion. Moreover, PSBP strongly inhibits the human mixed lymphocyte reaction. Taken together, the present data support evidence for a new type of function for PSBP. We report that PSBP is a potent immunosuppressor factor and we describe its effect on the immune function in vitro. Here, we discuss the possible implications of these findings in the protection of sperm from immunologic damage in the feminine reproductive tract.

Colocalization of androgen binding protein, oxytocin receptor, caveolin 1 and proliferation marker p21 in benign prostate hyperplasia.

Androgen-binding protein (ABP) and oxytocin (OT) are among the factors that control smooth muscle proliferation and tumour growth through oxytocin receptor (OTR). A close functional interaction of OTR and caveolin 1 has been shown to modulate cell growth and proliferation. We investigated samples from 10 patients (mean age 68.3) who underwent transurethral prostate resection because of benign prostate hyperplasia (BPH) by immunohistochemistry. Post-mortem prostate samples of three young men (age 18, 28, 33) were used as controls. Tissue samples were embedded in epoxy resin and cut into serial 1 microm sections for colocalization of ABP, OTR, proliferation marker p21 and caveolin 1. ABP was found in stroma of the smooth muscle cells in all studied samples. OTR staining occurred in most of these cells in BPH while controls contained only scattered cells positive for OTR. There were no apparent differences in immunostaining for p21 while immunoreactivity for caveolin 1 was observed in most cells in BPH and only in few cells in controls. Caveolin 1 was mostly colocalized with ABP and OTR in BPH samples while controls did only occasionally show this colocalization. Our observations indicate an interaction of ABP and OTR, associated with caveolin 1, which may account in part for known non-genomic actions of gonadal steroids. Androgen dependent prostate growth in BPH may be linked to these mechanisms.

[Characterization and partial purification of androgen binding proteins from human prostate].

The prostate is one of the target organs of androgen. This fact is the foundation of the anti-androgen therapy for the treatment of prostatic of cancer as there are many prostatic cancers which show no response to hormone therapy. Since androgen acts via an androgen-androgen receptor complex in cytosol, trials to predict the effectiveness of the anti-androgen therapy for the treatment of prostatic cancers by means of the measurement of androgen receptor (AR) have been done. However some investigators emphasize that the response to hormone therapy and the contents of AR are not necessarily parallel. This discrepancy is probably due to the inaccurate measurement of AR. AR is measured by a radio-receptor-assay method, but it is possible that androgen binding proteins other than AR are also measured by the radioreceptor-assay method. In the human prostatic tissues, there are several androgen binding proteins other than AR. These are mainly testosterone-binding globulin (TeBG) and progesterone-binding protein (PBP). In this study, I attempted to separate and characterize androgen-binding proteins in human prostates. 500 g of benign prostatic hyperplasia (BPH) tissues obtained from patients undergoing retropublic or suprapubic prostatectomy were used. In order to separate these androgen-binding proteins, DEAE-cellulose ion exchange chromatography was used. Prostatic cytosol was applied on the DEAE-cellulose column. Two 3H-R1881 binding peaks were eluted: one was a flow-through fraction (peak I), and the other was an 0.1M KCl eluted fraction (peak II). When human serum was applied to the column, one 3H-DHT binding peak flowed through the column (peak III). It was thought that peak III contained TeBG. In order to ascertain whether AR was composed in peak I or peak II, an inhibition test by various non-radioactive steroids, R1881, DHT, testosterone, progesterone and estradiol was performed. 3H-R1881 binding of peak I was not inhibited by DHT or testosterone, while 3H-R1881 binding of peak II was inhibited by DHT and testosterone. The androgen-binding affinity of the peak I and peak II fraction was also measured using Scatchard's analysis. The dissociation constant of peak I was 6.25 nM, and that of peak II was 0.76 nM. Judging from these measurements the androgen-binding protein of peak II contained a specificity and high affinity to androgen. Consequently it was thought that AR was composed in peak II. Peak II fraction was applied on a Sephadex G200 gel chromatography column. A single androgen binding peak eluted in the void fraction.(ABSTRACT TRUNCATED AT 400 WORDS)

Sertoli cells of adult rats in vitro. III. Purification of androgen-binding protein from the culture medium.

A method giving a high yield for the isolation and purification of the androgen-binding protein (ABP) from the nutritional medium of cultured cells from adult rats is described.

Production of an antibody to mouse salivary androgen binding protein (ABP) and its use in identifying a prostate protein produced by a gene distinct from Abp.

We previously demonstrated polymorphism of a mouse salivary protein which, because of its ability to bind androgen, we designated androgen binding protein (ABP) and its structural gene, Androgen binding protein (Abp). This report describes the purification of salivary ABP and presents the amino acid composition of its subunits. Using an antibody raised against the purified protein, we demonstrated the presence of cross-reactive material (CRM) in mouse parotid, submaxillary, sublingual, and prostate glands by double immunodiffusion. Immunohistochemical detection of proteins on electroblots of polyacrylamide electrophoresis and isoelectric focusing gels, however shows that the prostate CRM is a protein with electrophoretic and isoelectric focusing behavior distinct from that of salivary ABP isoproteins. Because the DBA/2J strain has a variant of salivary ABP, that strain was analyzed to determine if a prostate ABP-CRM variant was present. The approach was hampered by an inability to detect CRM in the prostates of DBA/2J mice. Prostate CRM was detected, however, in some progeny from repeated backcrosses of DBA/2J X C3H/St hybrids to the C3H/St and DBA/2J parental strains. The prostate CRM detected in samples from animals heterozygous for salivary Abp appears to be identical to C3H/St prostate CRM, suggesting that the gene controlling prostate ABP-CRM is related to, but distinct from, Abp. The reason for reduced or absent CRM in the prostates of DBA/2J males is unknown but this finding suggests that there are strain-related differences in the expression of this prostate protein.

Partial purification of androgen binding protein from bull epididymis.

An androgen binding protein (ABP), with an equilibrium dissociation constant of 4.2 nM and a molecular weight of about 100 kDa, has been purified from bull epididymal extracts using a four-step procedure. These preliminary results underline the main difficulties encountered in the purification of this protein present at a very low concentration (i.e. 50-fold less than in rat or rabbit epididymides). Ammonium sulfate precipitation is not a suitable step due to the formation, in presence of salt, of insoluble material leading to a loss of ABP. Lipids, particularly phospholipids, might be implicated in this phenomenon. Several steps, including anion exchange in batch followed by concentration, affinity chromatography and HPLC gel filtration allowed us to obtain a 7667-fold purified protein with a 9% yield.

The presence of a hitherto undefined high-capacity androgen binding macromolecule in human ovarian cancer tissue.

Sex hormone binding globulin (SHBG) is known to interfere in the quantitation of androgen receptors (AR) if dihydrotestosterone (DHT) is used. We used a monoclonal antibody to remove SHBG from cytosol. In cytosol of benign prostatic hyperplastic (BPH) tissue low capacity binding for DHT, but not for R1881, was found after removal of SHBG. AR were detected in 18 of 20 ovarian cancer cytosols. In the two AR-negative cases, non-saturable binding for DHT, testosterone and R1881 was observed. Incubation with anti-SHBG did not change this. An hitherto undefined androgen binding macromolecule(s), with high-capacity binding for natural and synthetic androgens, but not for estrogen and progesterone, seems to be present in these ovarian cancer tissues. The functionality of these androgen binding macromolecules in ovarian cancer is yet to be demonstrated.

Evidence for an androgen binding protein in the testis of a teleost fish (Salmo gairdneri R.): a potential marker of Sertoli cell function.

A factor binding tritiated testosterone was detected using "steady-state" polyacrylamide-gel electrophoresis, in rainbow trout genital tract. It migrated with a Rf identical to that of rat ABP. This binding was thermolabile, and was competitively inhibited by unlabelled testosterone. The steroid binding protein was found in cytosols from trout testes which had been previously perfused to avoid blood contamination, trout seminal plasma and in testicular explants incubation media. Using a quantitative assay and a Scatchard analysis, 25-50 pmol binding sites per gram gonad were found in testis cytosol. Binding affinity constant for testosterone in the various samples was close to 4 x 10(8) M(-1). The dissociation of steroid-protein complex was rapid (t 1/2 approximately 1.5 min). Hormonal specificity was studied by the competition of 3H-T binding with several concentrations of unlabelled competitors and the following order for affinities was obtained: dihydrotestosterone approximately androstenedione greater than testosterone greater than oestradiol greater than 17 alpha, 20 beta DHP greater than 11KT greater than cyproterone acetate greater than cortisol. High testicular cytosol and seminal plasma concentrations and apparent in vitro production indicate that the testis may synthesize an ABP-like protein in the trout. Such a factor would provide a unique marker of Sertoli cell activity and regulation in various physiological or experimental situations.

Seminal fluid androgen binding protein.

The following study was undertaken to determine the presence of an androgen binding protein (ABP) in the ejaculate. Seminal fluid was obtained from ten fertile subjects. Sperm counts ranged from 20 x 106/cc to 80 x 106/cc. Each sample was preincubated with tritiated dihydrotestosterone (DHT) and examined by polyacrylamide gel electrophoresis (PAGE). Second, after preincubation of the samples with tritiated DHT, the samples were mixed with Concanavalin-A bound to sepharose-D (C-S) and the supernate separated and counted. Finally, saturation analysis of the samples using dextran-coated charcoal for separation and counted. Finally, saturation analysis of the samples using dextran-coated charcoal for separation was performed and Scatchard analysis was used to determine the concentration of ABP present. PAGE demonstrated ABP in seven of ten samples studied. The bound counts of DHT were removed by C-S. The concentrations of ABP ranged from 0.132 to 0.468 nanomoles ABP/dl semen. These data indicate there is an ABP in seminal fluid similar to that from the Sertoli cell.

Structural studies on rat prostatic binding protein. The primary structure of component C1 from subunit F.

The amino acid sequence of component C1, the polypeptide specific for subunit F of prostatic binding protein, the major secretory glycoprotein of the rat ventral prostate, has been determined. Its structure was established using the manual Edman degradation on the intact protein and on the most relevant fragments isolated from trypsin, chymotrypsin, thermolysin and Staphylococcus aureus protease digests of the 14C-labelled S-carboxamidomethylated component C1. Component C1 contains 88 amino acids corresponding to a molecular weight of 10246. It is an acidic polypeptide due to the presence of 17 acidic residues; its three cysteine residues are almost symmetrically distributed over the peptide chain. Highly polar regions are found in positions 17-27 and 37-47, while the C-terminal part of the molecule contains two hydrophobic segments.

Purification and characterization of androgen binding protein from the rat epididymis.

Androgen binding protein (ABP) was purified from rat epididymides by sequential ammonium sulfate precipitation, affinity chromatography, gel filtration, and DEAE ion exchange chromatography. The column matrix formed by coupling dihydrotestosterone-17 alpha-(hexanoic acidY to agarose via diisopropylamine was stable during the extensive washing required following application of crude tissue extracts to the affinity matrix. In addition, when used under the optimal conditions, the column produced a 1600-fold purified in a single step. Apparent homogeneity of the final product was shown by polyacrylamide gel electrophoresis, sedimentation equilibrium, and constant specific activity across the peak of the final chromatograph. The molecular weight determined by sedimentation equilibrium at pH 7.4 was 85 000. By contrast, the molecular weight determined by sedimentation equilibrium in guanidine.HCl and by sodium dodecyl sulfate-polyacrylamide gel electrophoresis was approximately one-half that of the native protein, suggesting that suggesting that ABP is comprised of subunits.

Variations in soluble and particulate ABP of rat testis during sexual development.

Androgen binding activity (ABP) was determined in two different fractions of developing rat testicular homogenates: in cytosol (cABP) and in a particulate fraction isolated by differential centrifugation (pABP). Homogenates were prepared under stabilization conditions by adding 350 nM testosterone to the homogenization buffer. cABP and pABP concentrations were maximal in 22- to 32-day-old animals, to decrease thereafter during sexual maturation. However, both cABP and pABP increased with age when results were expressed on a per organ basis. pABP could be solubilized under conditions in which it could retain its binding activity. It was then photoaffinity labeled and chromatographed on a Sephadex G 200 column using cytosolic epididymal ABP as a control. Similarities between cABP and pABP include not only the same androgen binding characteristics but also the same exclusion volume after Sephadex G 200 chromatography. Since pABP is only present in Sertoli cells, it might represent ABP before being secreted. Because of its intracellular localization, it could play a role in the compartmentalization of androgens within the testis.

Crystallization of prostatic binding protein.

Prostatic binding protein is a dimeric glycoprotein capable of binding a variety of steroids. This protein is a major component of rat prostate cytosol making it possible to purify milligram quantities. Hexagonal crystals of X-ray diffraction quality have been grown from phosphate buffered ammonium sulfate solution by vapor diffusion methods. These crystals which are reasonably stable to X-rays, show diffraction to 6.3 A and belong to space group P6(1) or P6(1)22 or the enantiomorphs. The unit cell has dimensions a = 88.7(5) A, c = 405(2) A, contains 24 molecules and has a specific volume of 2.8 A3/Dalton.